Up to date, expert answers to frequently asked questions (FAQ) about oxygen supply systems, respiratory care and pulse oximetry written by OCC & collaborators.
What about patients who are pregnant, or considering becoming pregnant?
▪ Consensus does not exist on the recommendation of NMV/r for pregnant patients. The US FDA and NIH state that for a mother and unborn baby, the benefit of taking NMV/r may be greater than the risk from the treatment, given existing animal studies and the extensive use of ritonavir in pregnant women with HIV. By contrast, WHO states that their strong recommendation for its use does not apply to pregnant patients. Decision making regarding prescription of NMV/r should be made in consultation between the patient and the health care worker, considering specific risks and benefits.
▪ Molnupiravir should not be used in pregnancy, and both men and women should be counseled to use a reliable method of contraception to avoid pregnancy within four days (females) and three months (males) of completing the course of molnupiravir.
-By EPiC FHI360